FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914561611> ?p ?o ?g. }

• W2914561611 abstract "Hyperpigmentation or dark patches on skin have been increasingly reported over past few decades. Overproduction of melanin by irregular melanogenesis due to high exposure of ultraviolet contributes to many aesthetic problems. Excessive exposure to ultraviolet radiation causes elevation of alpha-melanocyte stimulating hormone (α-MSH) production leading to undesired pigmentation process. Whitening and bleaching agents are among the therapeutic choices in treating hyperpigmentation. However, some of these whitening agents such as kojic acid and hydroquinone were claimed to exhibit detrimental effects while others such as arbutin and ascorbic acid demonstrated low efficacy as depigmenting agent. Thus, alternative therapeutics preferences were derived from natural products in effort to provide safe yet reliable depigmenting agents. Chalcone and its derivatives have been reported to have pharmaceutical effect of depigmenting activity. In the present study, ten chalcone derivatives were screened for anti-tyrosinase activity using mushroom tyrosinase assay. Effects of selected chalcone derivatives on cellular melanin production as well as tyrosinase activity were evaluated in α-MSH-stimulated B16-F10 cells. The chalcone derivatives were further elucidated for melanogenic genes expressions of Tyr, Trp-1, Trp-2 and Mitf. Out of ten compounds, seven demonstrated promising anti-tyrosinase activity which were 3-(4-Amino-phenyl)-1-(4-hydroxy-phenyl)-propenone (AQ), 1-(2-Hydroxy-4,6-imethoxyphenyl)- 3-phenyl-propenone (FLB), 1-(2-Hydroxy-4,6-dimethoxy-phenyl)-3-(4-methoxy-phenyl)-propenone (FLA), 1-(2,4-Dihydroxy-phenyl)-3-(2,3-dimethoxyphenyl)-propenone (E-5), 3-(3,4-Dihydroxy-phenyl)-1-(2-hydroxy-4,6-dimethoxyphenyl)-propenone (E-8), 3-(4-Chloro-phenyl)-1-(2,4-dihydroxy-phenyl)-propenone (EY-1) and 1-(5-Chloro-2-hydroxy-phenyl)-3-(3,4-dimethoxy-phenyl)-propenone (D- 32) with IC50 values of 15.95 ± 0.83μM, 15.74 ± 1.92 μM, 17.22 ± 1.21 μM, 17.70 ± 1.04 μM, 21.39 ± 1.12 μM, 28.18 ± 1.74 μM and 46.99 ± 2.54 μM respectively. Accordingly, toxicity effects of the potential chalcone derivatives were evaluated on α-MSH-stimulated B16-F10 cells using MTT assay whereby only FLA and FLB showed lowest cytotoxic effect with 82.25 ± 1.52 % and 80.41 ± 0.78 % of cell viability respectively. Reducing effects towards melanin content and cellular tyrosinase activity in α-MSH-stimulated B16-F10 cells indicated that FLA significantly reduced the specific cellular melanin content in cells by 7-fold (0.48 ± 0.04 μg melanin/μg protein) and FLB by12-fold (0.28 ± 0.04 μg melanin/μg protein). Specific cellular tyrosinase activity was inhibited by FLA and FLB by 11-fold (0.74 ± 0.04 μU/μg protein) and 20- fold (0.42 ± 0.02 μU/ μg protein) respectively. At molecular level, treatments of FLA and FLB suppressed all melanogenic genes expressions of Tyr, Trp-1, Trp-2 and Mitf in α-MSH-stimulated B16-F10 cells. Interestingly, at the highest concentration of 50 μM tested, both FLA and FLB showed highest suppression on Tyr gene by 20-fold (0.05 ± 0.01 fold expression) and 50-fold (0.02 ± 0.01 fold expression) respectively. Findings from the study have provided mechanistic insights for the depigmenting actions of chalcone derivatives on α-MSH-stimulated B16-F10 cells via suppression of melanogenic genes of Tyr, Trp-1, Trp-2 and Mitf. With these results, it could be extrapolated that by limiting the melanogenic responses of B16-F10 cells, the melanin production as well as tyrosinase activity associated with hyperpigmentation may be lessened by FLA and FLB. Thus, both chalcone derivatives could be used as lead compounds on developing new depigmenting agents." @default.
• W2914561611 created "2019-02-21" @default.
• W2914561611 creator A5079783500 @default.
• W2914561611 date "2014-10-01" @default.
• W2914561611 modified "2023-09-24" @default.
• W2914561611 title "Inhibition of melanogenic activity by chalcone derivatives in alpha-melanocyte stimulating hormone cell line (B16-F10)" @default.
• W2914561611 hasPublicationYear "2014" @default.
• W2914561611 type Work @default.
• W2914561611 sameAs 2914561611 @default.
• W2914561611 citedByCount "0" @default.
• W2914561611 crossrefType "dissertation" @default.
• W2914561611 hasAuthorship W2914561611A5079783500 @default.
• W2914561611 hasConcept C107538193 @default.
• W2914561611 hasConcept C16005928 @default.
• W2914561611 hasConcept C177504595 @default.
• W2914561611 hasConcept C181199279 @default.
• W2914561611 hasConcept C185592680 @default.
• W2914561611 hasConcept C2776728111 @default.
• W2914561611 hasConcept C2777524492 @default.
• W2914561611 hasConcept C2777658100 @default.
• W2914561611 hasConcept C2779078452 @default.
• W2914561611 hasConcept C2779538156 @default.
• W2914561611 hasConcept C2779769559 @default.
• W2914561611 hasConcept C2780764945 @default.
• W2914561611 hasConcept C2781424683 @default.
• W2914561611 hasConcept C45904493 @default.
• W2914561611 hasConcept C54355233 @default.
• W2914561611 hasConcept C55493867 @default.
• W2914561611 hasConcept C71240020 @default.
• W2914561611 hasConcept C71924100 @default.
• W2914561611 hasConcept C86803240 @default.
• W2914561611 hasConcept C87554066 @default.
• W2914561611 hasConcept C98274493 @default.
• W2914561611 hasConceptScore W2914561611C107538193 @default.
• W2914561611 hasConceptScore W2914561611C16005928 @default.
• W2914561611 hasConceptScore W2914561611C177504595 @default.
• W2914561611 hasConceptScore W2914561611C181199279 @default.
• W2914561611 hasConceptScore W2914561611C185592680 @default.
• W2914561611 hasConceptScore W2914561611C2776728111 @default.
• W2914561611 hasConceptScore W2914561611C2777524492 @default.
• W2914561611 hasConceptScore W2914561611C2777658100 @default.
• W2914561611 hasConceptScore W2914561611C2779078452 @default.
• W2914561611 hasConceptScore W2914561611C2779538156 @default.
• W2914561611 hasConceptScore W2914561611C2779769559 @default.
• W2914561611 hasConceptScore W2914561611C2780764945 @default.
• W2914561611 hasConceptScore W2914561611C2781424683 @default.
• W2914561611 hasConceptScore W2914561611C45904493 @default.
• W2914561611 hasConceptScore W2914561611C54355233 @default.
• W2914561611 hasConceptScore W2914561611C55493867 @default.
• W2914561611 hasConceptScore W2914561611C71240020 @default.
• W2914561611 hasConceptScore W2914561611C71924100 @default.
• W2914561611 hasConceptScore W2914561611C86803240 @default.
• W2914561611 hasConceptScore W2914561611C87554066 @default.
• W2914561611 hasConceptScore W2914561611C98274493 @default.
• W2914561611 hasLocation W29145616111 @default.
• W2914561611 hasOpenAccess W2914561611 @default.
• W2914561611 hasPrimaryLocation W29145616111 @default.
• W2914561611 hasRelatedWork W1175602589 @default.
• W2914561611 hasRelatedWork W2016647998 @default.
• W2914561611 hasRelatedWork W2024877560 @default.
• W2914561611 hasRelatedWork W2040372670 @default.
• W2914561611 hasRelatedWork W2060934806 @default.
• W2914561611 hasRelatedWork W2204229430 @default.
• W2914561611 hasRelatedWork W2734495127 @default.
• W2914561611 hasRelatedWork W2896020885 @default.
• W2914561611 hasRelatedWork W2896086184 @default.
• W2914561611 hasRelatedWork W2897838749 @default.
• W2914561611 hasRelatedWork W2905414591 @default.
• W2914561611 hasRelatedWork W2919242331 @default.
• W2914561611 hasRelatedWork W2929929496 @default.
• W2914561611 hasRelatedWork W2939357560 @default.
• W2914561611 hasRelatedWork W2963454233 @default.
• W2914561611 hasRelatedWork W2981528023 @default.
• W2914561611 hasRelatedWork W3037002398 @default.
• W2914561611 hasRelatedWork W3107778052 @default.
• W2914561611 hasRelatedWork W3113261331 @default.
• W2914561611 hasRelatedWork W3195483805 @default.
• W2914561611 isParatext "false" @default.
• W2914561611 isRetracted "false" @default.
• W2914561611 magId "2914561611" @default.
• W2914561611 workType "dissertation" @default.